Gene Therapy
Vectors
Inspired By Nature – Motivated by Health
What we offer
Unique approach
AAV Peptide display, combined with unique DNA barcoding and next generation sequencing allows for easy screening of AAV libraries containing millions of rationally designed, targeted AAV variants in a single screen.
Fast & Flexible
Choose your target, tissue type, cell population or application. rAAVen designs a targeted, rationally designed AAV peptide display library which can be combined by a generated library of promotor & enhancer elements for increased cell and tissue specific expression.
Translational at scale
rAAVen offers screening of the AAV peptide library in animal models ranging from rodents to non-human primates, ensuring that the delivered product translates within mammalian species and are prime candidates for clinical trials.
Advancing Gene Therapy Through Collaboration
At rAAVen Therapeutics, we are proud to collaborate with industry leaders and innovators to advance the frontiers of gene therapy. Our partners are integral to our mission of developing cutting-edge solutions and driving impactful change in the field of adeno-associated virus (AAV) technologies.
Partner with us
We love to connect with innovators who share our dedication to develop revolutionary gene therapies.
rAAVen News
rAAVen Partners with Prevail to Advance AAVs for Neurological Disorders
rAAVen Therapeutics is excited to announce a new partnership with Prevail Therapeutics to develop novel adeno-associated virus (AAV) capsids for disorders of the nervous system. (link)
rAAVen Appoints Magnus Henriks as Chief Executive Officer
rAAVen Therapeutics has hired Magnus Henriks as the Chief Executive Officer. Prior to joining rAAVen, Magnus has had leading positions in various commercial companies.
rAAVen and Myrtelle Expand Partnership for Capsid Validation
rAAVen Therapeutics has gone into an agreement, for a continuous partnership with Myrtelle, Inc. In the new collaboration rAAVen will validate a defined number of